Dr. Peter Facchini is a Professor of Metabolic Biochemistry at the University of Calgary and the Chief Innovation Officer at Enveric Biosciences Inc. (NASDAQ:ENVB). His research has led to the elucidation of several specialized metabolite biosynthetic pathways including those leading to morphine in opium poppy and mescaline in peyote. He recently led the development of a more rapidly hydrolysed analog of psilocybin, releasing the active moiety psilocin, and a non-hallucinogenic derivative of N,N-dimethyltryptamine (DMT) displaying neuroplastigenic, anxiolytic and anti-depressive properties. He is an inventor of more than 30 issued and pending patents, and he has co-founded six companies, two of which are publicly traded. His entrepreneurship has been recognized through innovation excellence awards from the University of Calgary and the Province of Alberta.